Using pH Gradient Dissolution with In-Situ Flux Measurement to Evaluate Bioavailability and DDI for Formulated Poorly Soluble Drug Products
- 165 Downloads
This study described a pH-gradient dissolution method combined with flux measurements as an in vitro tool for assessing the risk of bioavailability reduction due to drug-drug interactions (DDI) caused by acid reducing agents (ARAs). The device incorporates absorption chambers into USP II dissolution vessels, with fiber optic UV-probes monitoring concentration in situ. Dosage forms of Genentech BCS class II drugs, GDC-0810, GDC-0941, and compound A, were tested by starting the dissolution in either pH 1.6 or pH 4.0 media then converting to FaSSIF after 30 min. GDC-0810 showed no significant difference in flux between the two conversion experiments. A supersaturation phase was observed for GDC-0941 in the pH 1.6 experiments after media conversion to FaSSIF; however, it did not appear to occur in the pH 4.0 experiment due to low drug solubility at pH 4.0, resulting in a 95% decrease in flux compared to pH 1.6 experiment. The extent of flux reduction and the total accumulated API mass in the absorption chamber agreed well with the 89% reduction in mean Cmax and the 82% reduction in mean AUC from dog PK study between animals treated with pentagastrin and famotidine. Testing of the compound A optimized formulation tablets showed a 25% reduction in flux and in vitro absorbed amount by changing pH 1.6 to 4.0, correlating well with the AUC decrease in clinical studies. Good correlation between in vitro data and in vivo PK data demonstrated the applicability of the method for formulators to develop drug products mitigating DDI from ARAs.
KEY WORDSpH gradient dissolution in-situ flux measurement acid reducing agents (ARAs) drug-drug interactions (DDIs) dosage form
The authors would like to recognize contribution of Mr. Ram Lingamaneni of Pion Inc. (currently at Catalent) who helped collecting data presented in this paper. The authors would like to acknowledge Drs. Dawen Kou and Mark Ragains of Genentech for their input during the execution of the project, Dr. Gena Dalziel of Genentech for GDC-0941 discussions, and Dr. Lichuan Liu of Genentech for technical discussions on GDC-0810 during the manuscript preparation.
- 1.Elder DP. Effective formulation development strategies for poorly soluble active pharmaceutical ingredients (APIs). Am Pharm Rev. 2011;12(2):56–61.Google Scholar
- 4.Bhattachar SN, Perkins EJ, Tan JS, Burns LJ. Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus™ simulations to predict absorption. J Pharm Sci. 2011;100:4756–65.CrossRefPubMedGoogle Scholar
- 6.Lainé AL, Price D, Davis J, Roberts D, Hudson R, Back K, et al. Enhanced oral delivery of celecoxib via the development of a supersaturable amorphous formulation utilizing mesoporous silica and co-loaded HPMCAS. In J Pharm. 2016;512:118–25.Google Scholar
- 19.Klein S, Dressman JB. Comparison of drug release from metoprolol modified released forms in single buffer versus a pH-gradient dissolution test. Dissolution Technologies. 2006;13:6–11.Google Scholar
- 30.Zhu A, Ho MC, Gemski CK, Chuang BC, Liao M, Xia C. Utilizing in vitro dissolution-permeation chamber for the quantitative predication of pH-dependent drug-drug interactions with acid-reducing agents: a comparison with physiologically based pharmacokinetic modeling. AAPS J. 2016;18:1512–23.CrossRefPubMedGoogle Scholar
- 35.Borbás E, Nagy ZK, Nagy B, Balogh A, Farkas B, Tsinman O, et al. The effect of formulation additives on in vitro dissolution-absorption profile and in vivo bioavailability of telmisartan from brand and generic formulations. Eur J Pharm Sci. 2018;114(January):310–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0928098717306954 CrossRefPubMedGoogle Scholar